KPV, a three-amino-acid tripeptide derived from the C-terminal of alpha-melanocyte-stimulating hormone (α-MSH), received a favorable recommendation from the FDA PCAC on July 23, 2026, to be added to the 503A bulk substances list. This article covers KPV's mechanism, the preclinical evidence, and the regulatory context.
KPV is the tripeptide sequence lysine-proline-valine, isolated as the C-terminal fragment of alpha-melanocyte-stimulating hormone. Unlike α-MSH itself, KPV does not activate melanocortin receptors or trigger melanin production. It operates through different pathways, primarily the PepT1 transporter and NF-κB signaling, giving it a distinct anti-inflammatory profile. It is not FDA-approved as a drug and is studied strictly as a research compound.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted (with an 8–6 tally recommending KPV) to recommend adding KPV to the 503A list, citing potential use in wound healing and inflammatory conditions. This recommendation followed KPV's removal from the FDA's Category 2 (safety-concern) list in April 2026. The FDA has not yet issued a final ruling, but the PCAC recommendation signals regulatory openness to compounding use.
The strongest single dataset is a 2008 publication in *Gastroenterology* showing that oral KPV reduced intestinal inflammation in two mouse colitis models. The mechanism involved:
Subsequent preclinical studies have examined KPV in models of inflammatory bowel disease, skin inflammation, and wound healing, with results generally consistent with anti-inflammatory and immunoregulatory activity.
As of August 2026, no completed human clinical trials on KPV have been published. All available evidence is from cell culture and animal models (primarily mice). The regulatory pathway has opened for compounding use, but this is a determination of safety, not efficacy. Researchers and clinicians should understand that KPV remains an unproven compound in humans.
To establish KPV's clinical role, research would need to include:
We supply KPV for preclinical research, with HPLC purity documentation and certificates of analysis:
Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.